Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Become the best at Discussion: 6 Procedures for Progress11.08.2023 - 2Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds17.11.2025
- 3Figure out How to Put resources into Lab Precious stones17.10.2023
- 4Famous Rough terrain Vehicles for 202405.06.2024
- 5A rare whale is having an encouraging season for births. Scientists warn it might still go extinct05.01.2026
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Texas cities have some of the highest preterm birth rates in the US, highlighting maternal health crisis nationwide
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- 'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
- ‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Instructions to Upgrade the Security Elements of Your Kona SUV
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
